Waters Corporation

Executive Summary

Waters Corporation (NYSE: WAT) is a leading provider of analytical instruments and software, specializing in liquid chromatography, mass spectrometry, and thermal analysis. Serving pharmaceutical, life sciences, industrial, clinical, and food safety markets, its technologies are critical for drug discovery, quality control, and compliance. With a direct global sales and service network, Waters generates recurring revenue from consumables and service contracts, supporting a resilient business model. Despite near-term headwinds from biopharma spending caution and currency volatility, Waters benefits from secular trends in precision medicine, biologics characterization, and food safety testing. Its strong installed base and deep customer relationships position it to capture growth as end markets recover.

Upcoming Catalysts (preview)

• Q1 2026Launch of Next-Generation UPLC and LC-MS Systems80% success
• Q2 2026Expansion in Biopharmaceutical Characterization Partnerships70% success
• Q1 2026FDA or Regulatory Approval for New Informatics Software Platform60% success